Name: An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis (Video) | JoVE Journal
Uploaded: 2019-09-12T13:00:00.000+00:00
Duration: 6 s
Description: Learn to develop an orthotopic hepatocellular cancer mouse model using intrasplenic injection of MTD2 hepatocytes in C57BL/6 mice. This method mimics human liver cancer immune features for studying tumor immunotolerance and therapeutic responses.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work is supported by NIH/NCI R01 CA164335-01A1 (K. F. Staveley-O&#8217;Carroll, PI) and NIH/NCI R01CA208396 (Mark Kester, Guangfu Li, Kevin F. Staveley-O&#8217;Carroll).

NOTE: All the procedure including animal subjects have been approved by the IACUC at the University of Missouri. All mice received humane care according to the criteria outlined in the &#34;Guide for the Care and Use of Laboratory Animals&#34;. The following procedure for cell isolation and inoculation should be performed in a hood. All performers should wear the standard personal protective equipment for handling of the mice and tissue.
1. Induction of Liver Fibrosis and Cirrhosis with IP Injection of Carbon Tetrachloride (CCl4)
NOTE: See Figure 1. (CCl4 is highly hazardous reagent, it should be handled carefully and with wearing chemical-resistant gloves)
<ol>
	<li>Obtain male C57BL/6J mice that are six to eight weeks old (see Table of Materials).</li>
	<li>Prepare 10% CCl4 (v/v) solution in corn oil in a centrifuge tube. Determine total volume based on number of mice to be injected (see step 1.6).</li>
	<li>Use appropriate mice handling technique to select one mouse for injection.</li>
	<li>Manually restrain the mouse with its dorsal (abdomen) side up.</li>
	<li>Clean the injection site on abdominal wall of the mouse by scrubbing with 70% alcohol.</li>
	<li>Inject male C57BL/6J mice with 160 &#181;L of 10% CCl4 solution by intraperitoneal (IP) injection using a 25-gauge disposable needle.</li>
	<li>Ensure that the needle penetrates just through the abdominal wall (approximately 4-5 mm) with bevel-side up and slightly angled at 15-20 degrees.</li>
	<li>Inject mice twice a week for a total of four weeks-each mouse will receive a total of eight injections. 
	NOTE: Two weeks after the last injection, treated mice are ready for ISPL inoculation of oncogenic hepatocytes from MTD2 mice.</li>
</ol>
2. Isolating Tag-transgenic Hepatocytes from Line MTD2 mice
NOTE: See Table 1 for solution recipes.
<table fo:keep-together.within-page="1">
	<tbody>
		<tr>
			<td>10x Earle&#8217;s Balanced Salt Solution without Ca or Mg (EBSS without Ca or Mg)</td>
			<td>4 g KCl 
			68 g NaCl 
			1.4 g NaH2PO4&#183;H2O 
			10 g dextrose 
			Add water to 1 liter, pH to 4.32 
			Pass through filter</td>
		</tr>
		<tr>
			<td>Solution 1</td>
			<td>20 mL 10x EBSS without Ca or Mg 
			44 g NaHCO3 
			1.33 mL 1.5M Hepes 
			10 mL of 10 mL EGTA 
			Add water to 200 mL</td>
		</tr>
		<tr>
			<td>Solution 2</td>
			<td>100 mL 10x EBSS 
			2.2 g NaHCO3 
			6.67 mL 1.5 M Hepes 
			Add water to 1 liter</td>
		</tr>
		<tr>
			<td>0.75% collagenase solution</td>
			<td>15 mg collagenase type 1 
			20 mL of solution 2</td>
		</tr>
		<tr>
			<td>Complete Medium</td>
			<td>2 RPMI 
			50 mL FBS 
			5 mL 100x Penicillin-Streptomycin</td>
		</tr>
	</tbody>
</table>
Table 1: Solution recipes.
<ol>
	<li>Obtain line MTD2 mice38 to serve as the source of oncogenic hepatocytes.</li>
	<li>Anesthetize 5-week-old MTD2 mice using 2.5% isoflurane. 
	NOTE: Proper anesthetization will be checked by toe pinch method. In brief, using two fingers, give the mouse toe/foot a good squeeze. If there is no withdrawal reaction, the animal is judged deep enough to commence surgery.</li>
	<li>When adequately sedated, place mice in a supine position and fix the extremities with tape to provide adequate exposure of abdominal surface.</li>
	<li>Perform a midline laparotomy incision using scissors along the length of the linea alba large enough to provide an adequate exposure of the liver.</li>
	<li>Displace the intestines to the left to provide better exposure of the liver and portal triad.</li>
	<li>Dissect above the liver to expose the inferior vena cava (IVC).</li>
	<li>Ligate the IVC above the liver using an artery clamp.</li>
	<li>Returning to the inferior border of the liver, use a butterfly needle (see materials) to gain IV access to the portal vein. Fix catheter by hand.</li>
	<li>Successively perfuse the mouse liver using an injection syringe at 8.9 mL/min with with 15 mL of solution 1, 15 mL of 0.75% collagenase solution 2, and 15 mL of solution 2 via the catheter.</li>
	<li>Harvest the perfused liver by cutting and taking the tumor mass from MTD2 mice in a 50 mL conical tube with 10-15 mL of PBS.</li>
	<li>Remove PBS and wash an additional time with PBS; do not centrifuge at this step.</li>
	<li>Cut the liver into smaller pieces using scissors and then wash again with PBS &#160;2x to remove remaining blood.</li>
	<li>Add 5 mL of complete RPMI medium to the conical tube and continuously mince the liver with scissors to small pieces (&#60;3 mm)-tissue should smoothly go through a 5 mL pipette.</li>
	<li>Add complete RPMI to a final volume of 30 mL and suspend liver using a 5 mL pipette.</li>
	<li>Filter the mixed solution with a 70 &#181;m strainer into a 50 mL conical tube.</li>
	<li>Wash the strainer several times with complete RPMI and adjust the final volume to 50 mL by adding additional RPMI medium.</li>
	<li>Quickly spin the suspension by centrifuge to a maximum of 500 rpm; once the speed is accelerated to 50 x g, the centrifuge should be stopped.</li>
	<li>Decant the supernatant and suspend pellets in 20 mL of PBS.</li>
	<li>Count cells using Trypan blue exclusion and a hemocytometer, then adjust the cell concentration to 2.5 x 106/mL for the following cell inoculation. 
	NOTE: The expected yield from 5 grams of tumor tissue is 80 million hepatocytes with viability &#62;95%.</li>
</ol>
3. Inoculating the hepatocytes from MTD2 mice to the liver of wild type C57BL/6J mice by ISPL injection
<ol>
	<li>The aseptic technique should be used in all the procedures</li>
	<li>Anesthetize the CCl4-treated male C57BL/6J mice with 2.5% isoflurane, the mice should be treated with eye lube to prevent eyes from drying out.</li>
	<li>Prepare syringes with 200 &#181;L of hepatocytes for injection.</li>
	<li>When adequately sedated, position mice with left side up.</li>
	<li>Shave the entire left flank of the mice, then scrub the area, alternating between 70% alcohol and betadine three times.</li>
	<li>Administer 5 mg/kg of carprofen subcutaneouly prior to surgical incision.</li>
	<li>Make a 1 cm incision on the left flank parallel to the 13th rib from the dorsal extreme beginning just below the spine muscle.</li>
	<li>Identify the spleen, then exteriorize it using blunt-pointed forceps.</li>
	<li>Clip the spleen with two medium-sized titanium clips. Place both clips between the splenic artery and vein, leave room between the clips to cut later after inoculation. 
	NOTE: The goal is to isolate the inferior pole of the spleen to reduce risk of seeding.</li>
	<li>Inject 200 &#181;L (0.5 million) of the prepared hepatocytes into the inferior pole of the spleen using a 27 G needle.</li>
	<li>Clip the inferior branch of the pedicle (inferior splenic pole vessels) with one medium-sized clip.</li>
	<li>Cut the spleen between the two initially placed clips.</li>
	<li>Remove the inferior pole of the spleen that was directly injected with tumor cells.</li>
	<li>Use 3-0 polyglactin 910 interrupted suturing to close the inner muscle layer.</li>
	<li>Use sterilized steel wound clips to close the outer skin layer. 
	NOTE: Steel clips are preferred over sutures to avoid animals chewing out sutures, leaving a gaping wound.</li>
	<li>Administer 5 mg/kg of carprofen subcutaneously after suture.</li>
	<li>Place all recovering animals on a temperature-controlled heating pad and monitor closely until fully recovered from anesthesia.</li>
	<li>Give mice free access to water after surgery. If the mouse becomes dehydrated during surgery, administer subcutaneous fluids (&#60;1 mL).</li>
	<li>Remove skin clips at 7-10 days post-operatively.</li>
</ol>

<ol><li>O'Connor, S., Ward, J. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatocellular+carcinoma+-+United+States%5BTitle%5D)+AND+%22Morbidity+and+Mortality+Weekly+Report%22%5BJournal%5D)">Hepatocellular carcinoma - United States.</a> Morbidity and Mortality Weekly Report. 59, 517-520 (2010).</li>
<li>Petrick, J., Kelly, S., Altekruse, S., McGlynn, K., Rosenberg, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Future+of+Hepatocellular+Carcinoma+Incidence+in+the+United+States+Forecast+Through+2030%5BTitle%5D)+AND+%22Journal+of+clinical+oncology%3A+official+journal+of+the+American+Society+of+Clinical+Oncology%22%5BJournal%5D)">Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.</a> Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 34, 1787-1794 (2016).</li>
<li>Greten, T., Lai, C., Li, G., Staveley-O'Carroll, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeted+and+Immune-based+Therapies+for+Hepatocellular+Carcinoma%5BTitle%5D)+AND+%22Gastroenterology%22%5BJournal%5D)">Targeted and Immune-based Therapies for Hepatocellular Carcinoma.</a> Gastroenterology. 156, 510-524 (2019).</li>
<li>Llovet, J., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., Gores, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatocellular+Carcinoma%5BTitle%5D)+AND+%22Nature+reviews.+Disease+primers%22%5BJournal%5D)">Hepatocellular Carcinoma.</a> Nature reviews. Disease primers. 2, 16018(2016).</li>
<li>Ding, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Precision+medicine+for+hepatocellular+carcinoma%3A+driver+mutations+and+targeted+therapy%5BTitle%5D)+AND+%22Oncotarget%22%5BJournal%5D)">Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.</a> Oncotarget. 8, 55715-55730 (2017).</li>
<li>Colombo, M., Maisonneuve, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Controlling+liver+cancer+mortality+on+a+global+scale%3A+still+a+long+way+to+go%5BTitle%5D)+AND+%22Journal+of+Hepatology%22%5BJournal%5D)">Controlling liver cancer mortality on a global scale: still a long way to go.</a> Journal of Hepatology. 67, 216-217 (2017).</li>
<li>Llovet, J., Burroughs, A., Bruix, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatocellular+carcinoma%5BTitle%5D)+AND+%22Lancet%22%5BJournal%5D)">Hepatocellular carcinoma.</a> Lancet. 362, 1907-1917 (2003).</li>
<li>Parkin, D., Bray, F., Ferlay, J., Pisani, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Estimating+the+world+cancer+burden%3A+Globocan+2000%5BTitle%5D)+AND+%22International+Journal+of+Cancer%22%5BJournal%5D)">Estimating the world cancer burden: Globocan 2000.</a> International Journal of Cancer. 94, 153-156 (2001).</li>
<li>Thomas, M., Zhu, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepocellular+carcinoma%3A+the+need+for+progress%5BTitle%5D)+AND+%22Journal+of+Clinical+Oncology%22%5BJournal%5D)">Hepocellular carcinoma: the need for progress.</a> Journal of Clinical Oncology. 23, 2892-2899 (2005).</li>
<li>Llovet, J., Bruix, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Molecular+targeted+therapies+in+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Hepatology%22%5BJournal%5D)">Molecular targeted therapies in hepatocellular carcinoma.</a> Hepatology. 48, 1312-1327 (2008).</li>
<li>Bruix, J., Sherman, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Management+of+hepatocellular+carcinoma%3A+an+update%5BTitle%5D)+AND+%22Hepatology%22%5BJournal%5D)">Management of hepatocellular carcinoma: an update.</a> Hepatology. 53, 1020-1022 (2011).</li>
<li>Pang, T., Lam, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Surgical+management+of+hepatocellular+carcinoma%5BTitle%5D)+AND+%22World+Journal+of+Hepatology%22%5BJournal%5D)">Surgical management of hepatocellular carcinoma.</a> World Journal of Hepatology. 7, 245-252 (2015).</li>
<li>Llovet, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Design+and+endpoints+of+clinical+trials+in+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Journal+of+the+National+Cancer+Institution%22%5BJournal%5D)">Design and endpoints of clinical trials in hepatocellular carcinoma.</a> Journal of the National Cancer Institution. 100, 698-711 (2008).</li>
<li>Mueller, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+immunology+and+immunotherapy.+Realizing+the+promise.+Introduction%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Cancer immunology and immunotherapy. Realizing the promise. Introduction.</a> Science. 348, 54-55 (2015).</li>
<li>Gajewski, T., Schreiber, H., Fu, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Innate+and+adaptive+immune+cells+in+the+tumor+microenvironment%5BTitle%5D)+AND+%22Nature+Immunology%22%5BJournal%5D)">Innate and adaptive immune cells in the tumor microenvironment.</a> Nature Immunology. 14, 1014-1022 (2013).</li>
<li>Ribas, A., Wolchok, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Combining+cancer+immunotherapy+and+targeted+therapy%5BTitle%5D)+AND+%22Current+Opinion+in+Immunology%22%5BJournal%5D)">Combining cancer immunotherapy and targeted therapy.</a> Current Opinion in Immunology. 25, 291-296 (2013).</li>
<li>Postow, M., Callahan, M., Wolchok, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+checkpoint+blockade+in+cancer+therapy%5BTitle%5D)+AND+%22Journal+of+Clinical+Oncology%3A+Official+Journal+of+the+American+Society+of+Clinical+Oncology%22%5BJournal%5D)">Immune checkpoint blockade in cancer therapy.</a> Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 33, 1974-1982 (2015).</li>
<li>Gao, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((VISTA+is+an+inhibitory+immune+checkpoint+that+is+increased+in+ipilimumab+therapy+in+patients+with+prostate+cancer%5BTitle%5D)+AND+%22Nature+Medicine%22%5BJournal%5D)">VISTA is an inhibitory immune checkpoint that is increased in ipilimumab therapy in patients with prostate cancer.</a> Nature Medicine. 23, 551-555 (2017).</li>
<li>Hahn, A., Gill, D., Pal, S., Agarwal, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+future+of+immune+checkpoint+cancer+therapy+after+PD-1+and+CTLA-4%5BTitle%5D)+AND+%22Immunotherapy%22%5BJournal%5D)">The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.</a> Immunotherapy. 9, 681-692 (2017).</li>
<li>Remon, J., Besse, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+checkpoint+inhibitors+in+first-line+therapy+of+advanced+non-small+cell+lung+cancer%5BTitle%5D)+AND+%22Current+Opinion+in+Oncology%22%5BJournal%5D)">Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.</a> Current Opinion in Oncology. 29, 97-104 (2017).</li>
<li>Kudo, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+checkpoint+blockade+in+hepatocellular+carcinoma%3A+2017+update%5BTitle%5D)+AND+%22Liver+Cancer%22%5BJournal%5D)">Immune checkpoint blockade in hepatocellular carcinoma: 2017 update.</a> Liver Cancer. 6, 1-12 (2017).</li>
<li>Kudo, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+checkpoint+inhibition+in+hepatocellular+carcinoma%3A+Basics+and+ongoing+clinical+trials%5BTitle%5D)+AND+%22Oncology%22%5BJournal%5D)">Immune checkpoint inhibition in hepatocellular carcinoma: Basics and ongoing clinical trials.</a> Oncology. 92, 50-62 (2017).</li>
<li>Breous, E., Thimme, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Potential+of+immunotherapy+for+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Journal+of+Hepatology%22%5BJournal%5D)">Potential of immunotherapy for hepatocellular carcinoma.</a> Journal of Hepatology. 54, 830-834 (2011).</li>
<li>Sprinzl, M., Galle, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Facing+the+dawn+of+immunotherapy+for+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Journal+of+Hepatology%22%5BJournal%5D)">Facing the dawn of immunotherapy for hepatocellular carcinoma.</a> Journal of Hepatology. 59, 9-10 (2013).</li>
<li>Liu, D., Staveley-O'Carroll, K., Li, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune-based+therapy+clinical+trials+in+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Journal+of+Clinical+Cell+Immunology%22%5BJournal%5D)">Immune-based therapy clinical trials in hepatocellular carcinoma.</a> Journal of Clinical Cell Immunology. 6, 376(2015).</li>
<li>Greten, T., Wang, X., Korangy, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Current+concepts+of+immune+based+treatments+for+patients+with+HCC%3A+from+basic+science+to+novel+treatment+approaches%5BTitle%5D)+AND+%22Gut%22%5BJournal%5D)">Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.</a> Gut. 64, 842-848 (2015).</li>
<li>Koster, B., de Gruijl, T., van den Eertwegh, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recent+developments+and+future+challenges+in+immune+checkpoint+inhibitory+cancer+treatment%5BTitle%5D)+AND+%22Current+Opinion+in+Oncology%22%5BJournal%5D)">Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.</a> Current Opinion in Oncology. 27, 482-488 (2015).</li>
<li>Johnson, D., Sullivan, R., Menzies, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immune+checkpoint+inhibitors+in+challenging+populations%5BTitle%5D)+AND+%22Cancer%22%5BJournal%5D)">Immune checkpoint inhibitors in challenging populations.</a> Cancer. 123, 1904-1911 (2017).</li>
<li>Li, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Programmed+cell+death-1+%28PD-1%29+checkpoint+blockade+in+combination+with+an+mTOR+inhibitor+restrains+hepatocellular+carcinoma+growth+induced+by+hepatoma+cell-intrinsic+PD-1%5BTitle%5D)+AND+%22Hepatology%22%5BJournal%5D)">Programmed cell death-1 (PD-1) checkpoint blockade in combination with an mTOR inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1.</a> Hepatology. 66, 1920-1933 (2017).</li>
<li>Heindryckx, F., Colle, I., van Vlierberghe, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Experimental+mouse+models+for+hepatocellular+carcinoma+research%5BTitle%5D)+AND+%22International+Journal+of+Experimental+Pathology%22%5BJournal%5D)">Experimental mouse models for hepatocellular carcinoma research.</a> International Journal of Experimental Pathology. 90, 367-386 (2009).</li>
<li>Qi, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+inCVAX%2C+in+situ+cancer+vaccine%2C+and+its+immune+response+in+mice+with+hepatocellular+cancer%5BTitle%5D)+AND+%22Journal+of+Clinical+and+Cellular+Immunology%22%5BJournal%5D)">Development of inCVAX, in situ cancer vaccine, and its immune response in mice with hepatocellular cancer.</a> Journal of Clinical and Cellular Immunology. 7, 438(2016).</li>
<li>Qi, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+a+radiofrequency+ablation+platform+in+a+clinically+relevant+murine+model+of+hepatocellular+cancer%5BTitle%5D)+AND+%22Cancer+Biology+and+Therapy%22%5BJournal%5D)">Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer.</a> Cancer Biology and Therapy. 16, 1812-1819 (2015).</li>
<li>Liu, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Sunitinib+represses+regulatory+T+cells+to+overcome+immunotolerance+in+a+murine+model+of+hepatocellular+cancer%5BTitle%5D)+AND+%22Oncoimmunology%22%5BJournal%5D)">Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.</a> Oncoimmunology. 7, 1372079(2017).</li>
<li>Staveley-O'Carroll, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vivo+ligation+of+CD40+enhances+priming+against+the+endogenous+tumor+antigen+and+promotes+CD8%2B+T+cell+effector+function+in+SV40+T+antigen+transgenic+mice%5BTitle%5D)+AND+%22Journal+of+Immunology%22%5BJournal%5D)">In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.</a> Journal of Immunology. 171, 697-707 (2003).</li>
<li>Avella, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regression+of+established+hepatocellular+carcinoma+is+induced+by+chemoimmunotherapy+in+an+orthotopic+murine+model%5BTitle%5D)+AND+%22Hepatology%22%5BJournal%5D)">Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.</a> Hepatology. 55, 141-152 (2012).</li>
<li>Li, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Successful+chemoimmunotherapy+against+hepatocellular+cancer+in+a+novel+murine+model%5BTitle%5D)+AND+%22Journal+of+Hepatology%22%5BJournal%5D)">Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.</a> Journal of Hepatology. 66, 75-85 (2017).</li>
<li>Li, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nanoliposome+C6-ceramide+increases+the+anti-tumor+immune+response+and+slows+growth+of+liver+tumors+in+ice%5BTitle%5D)+AND+%22Gastroenterology%22%5BJournal%5D)">Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in ice.</a> Gastroenterology. 154, 1024-1036 (2018).</li>
<li>Held, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((T+antigen+expression+and+tumorigenesis+in+transgenic+mice+containing+a+mouse+major+urinary+protein%2FSV40+T+antigen+hybrid+gene%5BTitle%5D)+AND+%22EMBO+Journal%22%5BJournal%5D)">T antigen expression and tumorigenesis in transgenic mice containing a mouse major urinary protein/SV40 T antigen hybrid gene.</a> EMBO Journal. 8, 183-191 (1989).</li>
<li>Hanahan, D., Weinber, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hallmarks+of+cancer%3A+the+next+generation%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Hallmarks of cancer: the next generation.</a> Cell. 144, 646-674 (2011).</li>
</ol>

There are none to declare.

With this protocol, we have established a reliable and reproducible murine model of HCC that mimics human HCC initiation and progression. Clinically, many risk factors successively induce liver injury, liver fibrosis, cirrhosis and the final stage of HCC. In our protocol, IP injection of CCl4 is used to first produce liver fibrosis in wild type mice, which allows the subsequent oncogenic hepatocytes to form the tumors in the setting of liver fibrosis. We found that tumor formation occurred most successfully in...

Hepatocellular cancer (HCC) is the most rapidly increasing type of cancer in the United States (US)1,2,3. Every year, approximately 850,000 new cases are diagnosed4,5 and 700,000 patients die from this lethal disease6,7,8,9,10, making it the second-highest cause of cancer-related death worldwide. Management of HCC includes surgical resection, transplantation, ablation, chemoembolization, or systemic therapies, such as sorafenib11. Early diagnosis and management with surgical resection or transplantation have the highest overall survival benefit4. Unfortunately, the majority of patients present at a later stage and require management with ablation, chemoembolization or sorafenib12. Sorafenib, a receptor tyrosine kinase inhibitor (RTKI), was approved by the Food and Drug Administration in 2008 as the only systemic drug therapy available for treating unresectable HCC. Although the drug only provides a modest increase in overall survival, from 7.9 to 10.7 months13, it provided a new therapeutic strategy that could be utilized to manage HCC.
Manipulating the immune system to eliminate established cancers is a rapidly growing field in cancer research14. Immune checkpoint studies have considerably advanced immunotherapeutic drug development in cancer treatment15,16. The FDA approved the use of antibodies (Abs) against cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand PD-L1 for the treatment of melanoma, lung cancer, head and neck cancer, and bladder cancer17,18,19,20. Clinical trials of monotherapy or combination therapy using one or multiple antibodies against PD-1, PD-L1, or CTLA-4 for the treatment of advanced HCC are ongoing21,22,23, and some trials have shown favorable results. In 2017, the FDA granted accelerated approval for anti-PD-1 antibody to treat HCC patients, who are resistance to sorafenib, but the overall response rate of this therapy is only 14.3%. Other strategies have not been translated into clinical practice at this time24,25. Overcoming tumor-induced profound immune tolerance to improve immune checkpoint therapy26; predicting efficacy of immune checkpoint therapy; preventing immune-related adverse events; optimizing administration route, dosage, and frequency; and finding effective combinations of therapies27,28,29 all remain extremely challenging tasks.
There are several conventional approaches used to induce HCC in mouse models currently and are utilized depending on the investigator&#39;s particular research question30. Chemically-induced HCC mouse models with genotoxic compounds mimic injury-induced malignancy. Xenograft models through either ectopic or orthotopic implantation of HCC cell lines are suitable for drug screening. A number of genetically modified mice have been engineered to investigate the pathophysiology of HCC. Transgenic mice expressing viral genes, oncogenes and/or growth factors allow the identification of pathways involved in hepatocarcinogenesis. Due to inherent limitations, these models do not recapitulate the typical immune characteristics seen in human HCC, which has significantly impeded elucidation of the underlying mechanisms and development of innovative immunotherapeutic strategies14,15. We recently created a clinically relevant murine model. This novel model not only mimics human HCC initiation and progression but also reflects most typical features of human disease including immune dysfunction. We have characterized its biological and immunological characteristics. Leveraging this novel model, we have explored various immunotherapeutic strategies to treat HCC31,32,33,34,35,36,37. This unique platform allows us to study mechanisms of tumor-induced immunotolerance and to develop proof-of-concept therapeutic strategies for HCC toward eventual clinical translation.

<table><tbody><tr><td>Anesthesia machine</td><td>VETEQUIP</td><td>IMPAC6</td><td>anesthesia machine for surgery</td></tr><tr><td>Butterfly needle</td><td>BD</td><td>8122963</td><td>Needle used for liver perfusion</td></tr><tr><td>C57BL/6 mice</td><td>Jackson Lab</td><td>000664&amp;nbsp;</td><td>mice used in prototol</td></tr><tr><td>Carprofen</td><td>CRESCENT CHEMICAL</td><td>20402</td><td>carprofen for pain release</td></tr><tr><td>Cell Strainer&amp;nbsp;</td><td>CORNING</td><td>REF 431751</td><td>Cell strainer, 70&amp;micro;m, for hepatocytes isolation</td></tr><tr><td>Centrifuge</td><td>Beckman Coulter</td><td>Allegra X-30R</td><td>centrifuge for cell isolation</td></tr><tr><td>Clips&amp;nbsp;</td><td>Teleflex Medical</td><td>REF 523700</td><td>Titanium Clips for spleen</td></tr><tr><td>Microscope</td><td>Zeiss</td><td>Primovert&amp;nbsp;</td><td>microscope for cell observation</td></tr><tr><td>Mtd2 mice</td><td>N/A</td><td></td><td>Gift from Dr. William A Held at roswell Park Cancer Institute in 2002, maintained in our lab</td></tr><tr><td>Needle</td><td>BD</td><td>REF 305109</td><td>BD precisionglide needle, 27G x 1/2 (0.4mm x 13mm)</td></tr><tr><td>Suture</td><td>ETHICON</td><td>J303H</td><td>coated VICRYL suture</td></tr><tr><td>SV40 T Ag antibody</td><td>Abcam</td><td>ab16879</td><td>anti-SV40 T-antigen antibody for IHC</td></tr><tr><td>Syringe</td><td>BD</td><td>REF 309626</td><td>1 mL TB syringe for cell injection</td></tr><tr><td>Trypan blue</td><td>SIGMA</td><td>T 8154</td><td>Trypan blue solution for cell viability test</td></tr><tr><td>Wound clips</td><td>Reflex</td><td>reflex9, Part. No. 201-1000</td><td>stainless steel wound clips for wound close</td></tr></tbody></table>

an oncogenic hepatocyte-induced orthotopic mouse model of hepatocellular cancer arising in the setting of hepatic inflammation and fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

The absence of a clinically relevant animal model addressing the typical immune characteristics of hepatocellular cancer (HCC) has significantly impeded elucidation of the underlying mechanisms and development of innovative immunotherapeutic strategies. To develop an ideal animal model recapitulating human HCC, immunocompetent male C57BL/6J mice first receive a carbon tetrachloride (CCl4) injection to induce liver fibrosis, then receive histologically-normal oncogenic hepatocytes from young male SV40 T antigen (TAg)-transgenic mice (MTD2) by intra-splenic (ISPL) inoculation. Androgen generated in recipient male mice at puberty initiates TAg expression under control of a liver-specific promoter. As a result, the transferred hepatocytes become cancer cells and form tumor masses in the setting of liver fibrosis/cirrhosis. This novel model mimics human HCC initiation and progression in the context of liver fibrosis/cirrhosis and reflects the most typical features of human HCC including immune dysfunction.

Oncogenic hepatocytes isolated from TAg-transgenic mice (Figure 2) were seeded in the liver of wild type mice by intra-splenic injection (Figure 3). The transplanted hepatocytes successfully and reliably grew orthotopic HCC tumors (Figure 4) with tumor specific antigen SV40 TAg (Figure 5) in the setting of hepatic inflammation and fibrosis (Figure 1).
<img alt="C57BL/6J mice in...

Here, we describe the development of a clinically relevant murine model of liver cancer recapitulating the typical immune features of hepatocellular cancer (HCC).

The absence of a clinically relevant animal model addressing the typical immune characteristics of hepatocellular cancer (HCC) has significantly impeded ...

an-oncogenic-hepatocyte-induced-orthotopic-mouse-model-hepatocellular

Research

JoVE Journal

Cancer Research

Infection of mice with an Adenovirus expressing the major human autoantigen cytochrome P450 2D6 (hCYP2D6) recognized by sera of patients suffering from type 2 autoimmune hepatitis results in a persistent form of autoimmune-mediated liver disease characterized by extensive hepatitis, fibrosis and generation of a CYP2D6-specific immune response.

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Human tumor xenografts in immunodeficient mice are valuable tools to study cancer biology.  Specific protocols to generate subcutaneous and intrahepatic xenografts from human hepatocellular carcinoma cells or tumor fragments are described.  Liver regeneration induced by partial hepatectomy in recipient mice is presented as a strategy to facilitate intrahepatic engraftment.

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Disruption of bile flow results in severe inflammatory cholestatic liver injury with a characteristic time-dependent sequence of morphological alterations. Here we present a protocol for the surgical ligation of the common bile duct in mice that allows to induce a strong fibrotic response after 21 to 28 days.

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

The metastatic spread of cancer is the major cause of cancer-related deaths. We provide an in-depth description of our survival surgery methodology for establishing a “patient-like” orthotopic syngeneic mouse model system for studying the mechanisms of metastasis in solid organ tumors.

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

This protocol provides a reliable method to establish humanized mice with both human immune system and liver cells. Dual reconstituted immunodeficient mice achieved via intrasplenic injection of human hepatocytes and CD34+ hematopoietic stem cells are susceptible to human immunodeficiency virus-1 infection and recapitulate liver damage as observed in HIV-infected patients.

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

This protocol presents a 3D biomimetic model with accompanying fibrotic stromal compartment. Prepared with physiologically relevant hydrogels in ratios mimicking the bio-physical properties of the stromal extracellular matrix, an active mediator of cellular interactions, tumor growth and metastasis.

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Portal vein injection of colorectal cancer (CRC) organoids generates stroma-rich liver metastasis. This mouse model of CRC hepatic metastasis represents a useful tool to study tumor-stroma interactions and develop novel stroma-directed therapeutics such as adeno-associated virus-mediated gene therapies.

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Here, we present a protocol to create orthotopic hepatocellular carcinoma xenografts with and without hepatic artery ligation and perform non-invasive positron emission tomography (PET) imaging of tumor hypoxia using [18F]Fluoromisonidazole ([18F]FMISO) and [18F]Fluorodeoxyglucose ([18F]FDG).

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Organoids generated from patient tumors are orthotopically injected into the mouse liver. The resection of non-tumorous liver tissue leads to a regenerative environment in the liver tissue where the tumor is located.

A Hepatocellular Cancer Patient&#45;Derived Organoid Xenograft Model to Investigate Impact of Liver Regeneration on Tumor Growth

The mouse model of partial 2/3 (66%) hepatectomy is well described in the literature, but more extended hepatectomies mimicking small-for-size syndrome after liver transplantation have seldom been used. We describe an extended 78% hepatectomy procedure in a mouse model that results in approximately 50% postoperative lethality in healthy mice.

Extended 78&#37; Hepatectomy in a Mouse Surgical Model

This protocol presents a comprehensive imaging pipeline to visualize and model hepatic stellate cells morphology in intact liver tissue. This approach combines fluorescent labeling of fibroblasts using mouse genetics, in situ liver perfusion-based tissue preparation, and a modified iDISCO tissue clearing method to achieve optical transparency.

Mapping Hepatic Stellate Cell Morphology in Mouse Models of Liver Fibrosis

Learn to develop an orthotopic hepatocellular cancer mouse model using intrasplenic injection of MTD2 hepatocytes in C57BL/6 mice. This method mimics human liver cancer immune features for studying tumor immunotolerance and therapeutic responses.

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis (Video) | JoVE Journal

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Explore More Videos